The REMS, originally designed to reduce the risk of clozapine-related neutropenia, has instead created substantial and avoidable barriers to basic care. As part of this REMS program, prescribers ...

Spravato has been approved since 2019 for TRD, with its label extended the following year as a rescue therapy for adults with major depressive disorder (MDD) who were at risk of self-harm or suicide.

Johnson & Johnson has priced its new Spravato nasal spray for treatment ... Firstly, it needs to be administered at certified treatment centres, and it also has a boxed warning on the risk of ...